Hyperfine, Inc. (HYPR): Nasdaq/NYSE listing notice — Hyperfine notifies Nasdaq of non-compliance with majority independent board requirement; cure period invoked

Hyperfine, Inc.

Effective Oct 24, 2022, director Maria Sainz may no longer be considered independent under Nasdaq Rule 5605(a)(2).
Company notified Nasdaq on Oct 24 that it is not in compliance with Majority Independent Board requirement (Rule 5605(b)(1)).
Hyperfine is relying on the cure period per Rule 5605(b)(1)(A) to regain compliance.
Company is actively searching for a qualified independent director to remedy the non-compliance.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Hyperfine, Inc. received a nasdaq deficiency notice notice regarding board independence (rules 5605(a)(2), 5605(b)(1), 5605(b)(1)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: board independence
Rules: 5605(a)(2), 5605(b)(1), 5605(b)(1)(A)

Exact text from the filing

October 24, 2022, Hyperfine, Inc. (the “Company”) believes that Maria Sainz, a current director of the Company and a member of the audit committee of the board of directors of the Company (the “Board”), may no longer be considered an Independent Director as defined in Nasdaq Listing Rule 5605(a)(2). As a result of Ms. Sainz’s no longer being considered an Independent Director, on October 24, 2022, the Company notified The Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications staff (the “Nasdaq Staff”) that the Company is not currently in compliance with the Majority Independent Board requi

View on SEC.gov

18 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Hyperfine, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-025062

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.